On June 24, Yuan Lin, Director of Drug Safety of State Drug Administration, and his delegation went to Sinopharm for investigation, Zhao Bingxiang, Deputy Secretary of Party Committee and General Manager of Sinopharm, hosted the reception, and the two sides held a symposium on drug regulation and high-quality development.

The meeting was presided over by Zhou Le, Deputy Director of the Department of Drug Administration. Director Yuan Lin and relevant comrades of the Department of Drug Registration and the Department of Drug Administration listened to the special reports on children's medicines, vaccines and blood products, special medicines, traditional Chinese medicines injections and formula granules, and drug business of Sinopharm Group's scientific and technological research and development, industrial manufacturing, and trading and circulation subsections, focusing on the research and development of medicines, manufacturing, supply management, quality assurance, informationization construction, modernization and logistics construction, and so on. Informatization construction, modern logistics construction and so on. Both sides had a full, in-depth and professional discussion and exchanges, focusing closely on the topics of drug regulation and high-quality development.

Yuan Lin affirmed Sinopharm's achievements in various aspects of operation and management, and at the same time put forward the following requirements: firstly, he hoped that Sinopharm would effectively raise its political position, coordinate the high-quality development of the pharmaceutical industry and high-level safety, and put the "four strictest" into practice; secondly, it would insist on observing the right and innovating, strengthen the responsibility of a state-owned central enterprise, strictly implement the responsibility of drug safety, continuously improve the drug regulatory system, and ensure the safety of pharmaceuticals, as well as the safety of the pharmaceutical industry. Secondly, we will adhere to the principle of integrity and innovation, strengthen the responsibility of state-owned central enterprises, strictly implement the responsibility for drug safety, continue to improve the drug regulatory system, and continuously strengthen the whole life-cycle regulatory system. We will continue to do a good job in the R&D and production of children's drugs, and strengthen the quality management of biological products, special drugs, traditional Chinese medicines and the whole chain and process of distribution.

Zhao Bingxiang said that NPMA will strictly follow the requirements of NPMA, put high-quality development in a prominent position, and play a good role in building a new development pattern of scientific and technological innovation, industrial control and safety support; fully implement the main responsibility of enterprises, further improve the quality management system, and strive to strengthen the scientific and technological innovation of pharmaceuticals, intelligent manufacturing, incubation capacity and the construction of supply and security capacity; grasp the key product management, and thoroughly study the national requirements in the field of pharmaceuticals. It will conduct in-depth research on what the country needs, what the people expect, what the industry tends to do and what the national medicines can do in the field of medicines, further optimize the allocation of resources and the product structure, and effectively provide the people with safer, more effective and more timely pharmaceutical services.

https://mp.weixin.qq.com/s?__biz=MzIyMzE1OTg3Nw==&mid=2247513451&idx=1&sn=baf9cf171c19da6c6f2dbb3200bc9694&chksm=e8208641df570f5701ee1de185390d6a5af6af506110afeb2e35bf69dbb50043d159ff45f838&mpshare=1&scene=1&srcid=0628nrEuf62ySFgDVY5Kaxhl&sharer_shareinfo=0f435f4920492e741f55411e75ff66c6&sharer_shareinfo_first=0f435f4920492e741f55411e75ff66c6#rd